TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
Go back to TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology| TG THERAP (NASDAQ: TGTX) | Delayed: 53.94 -0.46 (0.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.40 | 52 Week High | $14.87 | |||
| Open | $54.00 | 52 Week Low | $4.90 | |||
| Day High | $55.52 | P/E | N/A | |||
| Day Low | $52.70 | EPS | $-0.67 | |||
| Volume | 3,140,095 | |||||
